
Cervical cancer is a disease in which cancer cells are found in the tissues of the cervix. The cervix, the lower part of the uterus, connects the body of the uterus to the vagina. Nearly all cases of cervical cancer can be linked to the human papillomavirus, or HPV, a sexually transmitted virus.
The normal cervix is a healthy pink color and is covered with scale-like cells called squamous cells. The cervical canal is lined with another kind of cell called columnar cells. But the area where the two cells meet — called the squamocolumnar junction and transformation zone (T-zone) — is the most likely area for abnormal cells to develop. The T-zone is more exposed on the cervix of young women (teens through 20s), making them more susceptible to cervical infections.
Health care professionals use the Pap test to find cellular abnormalities in cervical tissue that has already or may become cancerous. The earlier cervical cancer is diagnosed, the better the chance for a cure. The American Cancer Society reports that both incidence and deaths from cervical cancer have declined markedly over the last several decades, due to more frequent detection of preinvasive and cancerous lesions of the cervix from increased Pap screening. There is a direct relationship between the use of the Pap smear as a screening tool for cervical cancer and the reduction of the incidence of cervical cancer, according to the American Society for Clinical Pathologists.
In its earliest stages, cervical cancer usually causes no symptoms. Irregular bleeding, bleeding or pain during sex, or vaginal discharge may be symptoms of more advanced disease. These symptoms should always be discussed with a health care professional.
All women are at risk for developing the disease, but several factors can increase a woman's risk of developing cervical cancer, according to the American Cancer Society:
More than twice as many African-American women die from cervical cancer as Caucasian women. Additionally, Hispanic women and Native-American women have higher rates of cervical cancer than Caucasian women. Rates of cervical cancer are also increasing among Vietnamese women. Lack of access to health services (and therefore, less screening), cultural influences and diagnosis of cancer at more advanced stages are all possible reasons for these differences.
Women of all ages are at risk of cervical cancer, but half of those diagnosed are between ages 35 and 55, with the average age of diagnosis of 47 years. Regardless, it is important that even postmenopausal women continue having regular Pap tests if they still have a cervix. Even if a woman's cervix was removed during a hysterectomy (as 90 percent are), if she had a suspicious Pap before her surgery, she should continue Pap tests.
The benefits of the Pap test are clear: The overall death rate in the United States from the disease has declined by 74 percent since the introduction of the Pap test in the 1950s.
Although both the incidence and death rates of cervical cancer are going down, it is still the 12th most common cancer in women, which may be related to the epidemic of infection with HPV. According to the CDC, approximately 20 million people are currently infected with HPV. As many as 75 percent of the reproductive-age population has been infected with one or more types of HPV, and up to 5.5 million new infections occur each year.
There are more than 100 different strains of HPV, and approximately 15 types have been linked to cancer of the cervix. While most women who develop cervical cancer have HPV, not all women with the virus will develop cervical cancer. In fact, only a small proportion of women infected with HPV develop cervical cancer. Some types of HPV cause vaginal and vulvar warts; other strains cause the warts that sometimes develop on the hands or feet.
New Vaccine Offers Protection Against HPV
Now there is something women can use to protect themselves against human papillomavirus (HPV)/cervical cancer in addition to regular Pap tests and safe sex: An HPV vaccine. The FDA recently approved the vaccine — called Gardasil — for women ages 13 to 26 after clinical trials showed the vaccine is safe and 100 percent effective in preventing HPV strains 16 and 18, which cause 70 percent of cervical cancers. Gardasil, given in three injections over six months, is also 99 percent effective in preventing HPV strains 6 and 11, which cause about 90 percent of genital wart cases. Although Gardasil prevents the bulk of HPV strains, it doesn't protect against all of them, so the FDA recommends it as a complement to Pap tests. Furthermore, the vaccine does not work if a woman is already infected with one of these HPV types. It has to be given before infection.
Last medical review: 6/06
Last date updated: 1/07
Copyright 2007 National Women's Health Resource Center Inc. (NWHRC)